Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 29 | 2021Novo Raises 2021 Guidance; Novo’s “Bigger Than Me” Anti-Obesity Awareness Campaign; Biocon’s Form 483 Observations Revealed; Novel Human Neo-Islet Technology PublishedPurchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, GLP-1RA + Basal, Other, SGLT2i Oct 28 | 2021Novartis’s Entresto Marketing Under DOJ Investigation?; Inventiva’s Ph2a Lanifibranor + Empa Trial (LEGEND); Merck and Sanofi Q3 ’21 Earnings Updates; Roche and Zur Rose Group CollaborationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Oct 27 | 2021Sinocare and EoFlow Diabetes Tech Collaboration; Provention Announces Positive Interim Results for Ph1 PROVENT Trial; Dario Partners with Virgin Pulse; Teva and Adocia Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other, SGLT2i Oct 26 | 2021Lilly and Novartis Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 25 | 2021Apple Watch 8 Reportedly Set to Include BGM; Lifescan Launches OneTouch Solutions; Xeris and Merck Collaboration; Dario Partners with New Employer Group; Tidepool Period Project Receives Financial SupportPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 22 | 2021Metacrine Discontinues NASH Program; Ikenna Ogbaa Joins GSK to Lead Daprodustat Medical Team; Biocon CY Q3 '21 (FY Q2 '22) Earnings Update; Integrity Applications Hires New President and COOPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other Oct 20 | 2021Viatris' Semglee Preferred on Express Scripts NPF; DreaMed’s Advisor Pro Launched in Leading Children’s Hospital; MiniMed 780G & Guardian 3 TIR In Pediatrics Comparable to Adults; Abbott and Roche Q3 '21 Earnings Updates; vTv Therapeutics Hires New President and CEO; Adhera Adds Target Indications for MLR-1023Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Oct 19 | 2021Lilly’s Ph3 Tirzepatide SURPASS-4 Results Published in Lancet; FDA Pre-Submission for rt-Glucose Salivary Test; Ultrahuman Hires Chief Business Officer; J&J Q3 ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Other Oct 18 | 2021Medtronic to Acquire Triple Jump?; Esperion to Reduce Workforce by 40%; Diamyd’s Ph3 T1DM Vaccine Trial Initiated; Vertex Announces Positive Results From Ph1/2 VX-880 TrialPurchase Blast
$599
Posted in: Other, SGLT2i Oct 15 | 2021Forxiga Pediatric Indication and Generic Sitagliptin Receive Positive CHMP OpinionsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 14 | 2021G&L Bs-glargine Completes Ph3; Adocia’s BC Lispro Cleared for Pivotal Ph3 in China; Dario Signs National Digital Behavioral Health ContractPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery Oct 13 | 2021Dexcom Launches Garmin Connect IQ Apps for Dexcom G6; Dexcom Expands TIR Educational Campaign in UKPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, SGLT2i Oct 12 | 2021vTv Therapeutics Announces Positive Results from TTP399 Mechanistic Trial; Non-Invasive CGM From Innovation Zed AdvancesPurchase Blast
$599
Posted in: Bolus Insulin, DPP-IVi, GLP-1RA, Other, SGLT2i Oct 11 | 2021Jardiance HFpEF Indication Filed in EU; Generic Sitagliptin (EMEA/H/C/005741) CHMP Decision?; October 11-14 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Oct 07 | 2021New NovoPen 6 Connected Pen Trial in T1DM (CONNECT 1); Lilly-sponsored Treprostinil/Sodium Citrate Infusion Site Pain Trial in T1DM; Dario Partners with New Employer Group; Ascensia Launches "This is Diabetes" CompetitionPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Glucose Monitoring, Other Oct 06 | 2021Medtronic Expands 630G/670G Pump Recall; Xeris Completes Acquisition of Strongbridge; DreaMed FDA Clearance for AI-based Clinical Decision Support System for T2DM; Know Labs Bio-RFID Readings Comparable to FDA-Cleared DevicesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other, SGLT2i Oct 04 | 2021BI/Lilly Launch Educational CVRM Game for HCPs; MannKind INHALE-1 Pediatric Study Enrolls First Patient; Dietitian-based Resource with PWD LaunchedPurchase Blast